GI medical oncologist @DanaFarber | @MayoMN_IMRES | @MUMedicine | Tweets my own. Interests: GI cancers, Clinical Trials, Targeting KRAS, #pancsm
Boston, MA
Joined May 2017
- Tweets1.7K
- Following525
- Followers1.2K
- Likes3.3K
Pinned Tweet
Results of randomized phase II #PDAC trial that will be a benchmark for future trials. Patients receiving 2nd-line gemcitabine/nab-paclitaxel alone after FOLFIRINOX had median OS of 6.6 months, the median PFS was 2.7 months, and the ORR was 2.9%.
⬇️⬇️⬇️
jamanetwork.com/journals/jam…
Brandon Huffman, MD retweeted
Please retweet - OR
please send your message of hope
OR both!
Feel free to screenshot your messages! All messages will be collected as part of this shared expression of hope.
@DrDanielKing @DavidHongMD @GarridoLagunaMD @kevansf @Sandra_Misale @EileenMOReilly @BHuffmanMD @BiachiTiago @MPishvaian @AmbrogioLab @FilippoPietran4 @DrShubhamPant @GIcancerDoc @DrMarkAwad @cjder23 @norbertkraut1 @CentralParkWMD @Aiims1742
This month, Revolution Medicines will donate $50 to @KRASKickers for every message of support submitted for up to $30,000. Plant a seed of hope. Share your message: revmed.com/revolution-ras/?u…
Brandon Huffman, MD retweeted
Great to be in Chicago for @ALLIANCE_org Fall Meeting with @EileenMOReilly, highlighting practice changing results of the ATOMIC study @FASinicropeMD
Brandon Huffman, MD retweeted
November is #PancreaticCancer Awareness Month – a perfect time for this episode of the Nice Genes! podcast produced by @GenomeBC, featuring @DanaFarber's @BHuffmanMD breaking down KRAS and what it means for treating patients with pancreatic cancer.
➡️bit.ly/4jXr0jk
💜 In honor of Pancreatic Cancer Awareness Month, it was an honor to participate in “Cracking #KRAS: Can We Finally Treat Pancreatic Cancer?” @GenomeBC @KRASKickers
Grateful to discuss advances in KRAS-targeted therapies and new hope for patients.
🎧 link.cohostpodcasting.com/42…
Brandon Huffman, MD retweeted
Randomized data shows PFS and OS benefit for SBRT/SABR for panc cancer. Congrats to Australasian GI Trials Group for completing this study. #radonc @Aiims1742 @TedHong9 @Dan_ChangMD @PrajnanDasMD @MikeChuongMD
sciencedirect.com/science/ar…
Updated efficacy and safety of initial cohorts for zecdarasib (INCB161734) with chemo (Abstract 3137RO) will be presented by Dr. @HollebecqueA at #ESMO26.
GnP combo ORR: 62.5%
FFX combo ORR: 75%
Looking forward to seeing the presentation! 👀
@KRASKickers #kras
🗣️ "[INCB161734] binds the switch II pocket of mutant KRAS with a G12D mutation with picomolar affinity, and it shows a greater than 80-fold selectivity over wild-type KRAS," said @BHuffmanMD of @DanaFarber on INCB161734 and how the phase 3 DAWN-303 trial is testing it in metastatic pancreatic cancer.
Full video 📰: onclive.com/view/dr-huffman-…
#pancsm #oncology
Brandon Huffman, MD retweeted
Thanks so much for coming, we enjoyed your talk immensely! Incredibly proud of where the PancCan field is headed.. #PDAC @DanaFarber @ASCO
Thank you for inviting me to talk about the evolving landscape in pancreatic cancer at the #MSCO Fall Conference! It was my pleasure to share our experience as these new treatments emerge for #PDAC. The future is targeting #KRAS.
Eloquent talk by @BHuffmanMD of @DanaFarber @DanaFarberNews at the #MSCO Fall conference in Minneapolis.
👏🥳👏🥳
@ASCO @ASCOPost @MayoCancerCare @MayoClinic @MayoMedEd @KLeventakos
Brandon Huffman, MD retweeted
WATCH 👀: @BHuffmanMD of @DanaFarber discusses INCB161734 and how the phase 3 DAWN-303 trial is testing it in metastatic pancreatic cancer.
See the whole video here ➡️: onclive.com/view/dr-huffman-…
#pancsm #oncology
Brandon Huffman, MD retweeted
Center for RAS Therapeutics at @DanaFarber
"The Dana-Farber Center for RAS Therapeutics is a multi-disciplinary initiative that seeks to advance novel treatment approaches to transform the lives of patients with RAS-driven cancers through scientific discovery, translational research, and clinical investigation.
The Center for RAS Therapeutics brings together expert clinicians and talented researchers to discover new RAS-targeted therapies and to provide patients with the most promising treatment options."
dana-farber.org/research/int…
dana-farber.org/research/int…
Brandon Huffman, MD retweeted
Thank you EHTG - European Hereditary Tumour Group for a fantastic meeting and for the opportunity to present our @DanaFarber data about Overall Survival of Individuals with Pancreatic Cancer Harboring Pathogenic Germline Variants in BRCA1, BRCA2, PALB2 and ATM.
Brandon Huffman, MD retweeted
"It means the world,” @DanaFarber’s @BHuffmanMD tells @WCVB about the FDA’s approval of the groundbreaking pancreatic cancer drug daraxonrasib. @DanaFarber_Hale
➡️bit.ly/4gFN5zP
Brandon Huffman, MD retweeted
FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by @DanaFarber and Brian Wolpin, MD, MPH, of @DanaFarber_Hale
RAS-ON-Q
🎉 🎉🎉
But I’ll probably still refer to it as RMC-6236 or daraxonrasib…🙂
For MedTwitter:
How do you say "Rasonque"?
Video Clips always appreciated.
@Aiims1742 @BHuffmanMD @EileenMOReilly @DavidHongMD @Sandra_Misale @GarridoLagunaMD
Incredible news for patients with pancreatic cancer today! It is just the beginning, but today is a great day!
Daraxonrasib (Rasonque) is FDA APPROVED for metastatic pancreatic adenocarcinoma after at least one prior systemic tx.
@DanaFarber_Hale @DanaFarber @KRASKickers
Today we approved a first-in-class targeted therapy for metastatic pancreatic cancer – one of the hardest cancers to treat. Today’s approval provides a critical new treatment for patients who’ve had very few options. fda.gov/news-events/press-an…
Brandon Huffman, MD retweeted
Looking forward to joining Dr. Huffman @DanaFarber today for a meaningful discussion on extending therapeutic breakthroughs in pancreatic cancer to older adults, and what we are doing @MSKCancerCenter to refine our treatment algorithm for these people. @CpcrMsk @EileenMOReilly
Join us at 12PM EST for a patient-centric webinar on the landscape for RAS inhibitors in older individuals with pancreatic cancer.
“Understanding RAS Inhibitors: New Cancer Therapies for Older Adults”
@MichaelMayMD @DanaFarber @letswinpc @KRASKickers
dfci.zoom.us/webinar/registe…
Join us at 12PM EST for a patient-centric webinar on the landscape for RAS inhibitors in older individuals with pancreatic cancer.
“Understanding RAS Inhibitors: New Cancer Therapies for Older Adults”
@MichaelMayMD @DanaFarber @letswinpc @KRASKickers
dfci.zoom.us/webinar/registe…